Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated May 3, 2021 (5 years ago)

1% Lidocaine HCl Injection (Lidocaine Hydrochloride)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

1% Lidocaine HCl Injection, USP, 300 mg/30 mL (10 mg/mL), 30 mL Single-dose vial (NDC 0409-4279-16), packaged in 25 vials per tray (NDC 0409-4279-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.

Affected NDCs 0409-4279-02 0409-4279-16

Compare with the code on your package — it is the most precise check available.

Drug: Lidocaine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Lidocaine Hydrochloride
NDC 00409-4279
10 mg/mL Injection, Solution
Epidural|infiltration|intracaudal|perineural
Hospira, Inc. Rx
Recalling firm
Pfizer, INC
NDC code
0409-4279-16
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0627-2021 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by Pfizer, INC

All 2021 recalls